A Novel Drug for Migraine
We are a clinical-stage company, unlocking the full therapeutic potential of optimized, multi-modal endocannabinoid system targeting to treat complex pain and CNS disorders.
The Opportunity
The market opportunity in migraine is immense.
Migraine is one of the world's most debilitating diseases.
Also one of most poorly managed. 60 - 80% of patients fail on 1st and 2nd line treatments.
$ 31 BN*
of addressable market size in the US.
* Research by LifeSci Consulting
The Science
Cannabinoids are one of the most exciting novel mechanisms in migraine science.
Cannabinoids engage multiple targets in and outside of the endocannabinoid system (ECS) to treat complex diseases like migraine via various validated pathways.
A combination of CBD:THC showed the greatest efficacy for migraine in an independent clinical trial at UC San Diego.
Cannabinoid drug development has major momentum globally, and was prioritized by a 2025 White House Executive Order.
Our Story
We are building first-in-class and best-in-class cannabinoid combinations for migraine.
InStitutional backing
$3.4M in NIH grants to advance into clinical trials
Momentum
Phase 1 clinical trial ongoing, phase 2 to start in 2026
RESEARCH PARTNERS
Issued Patents
USPTO issued CoM patents and layered IP strategy
Our Team
Our team are world-class leaders in cannabinoid and migraine drug development.
And we are supported by world-class advisors and partners
Stephen Wright MD
Former Chief Medical Officer
GW Pharmaceuticals
Messoud Ashina MD PhD
Former President
International Headache Society
Steve Kuemmerle PhD
Former Venture Head
Abbott
Gary Winer
Former CEO
Abbvie Japan
Rob Schickel PhD
Founder
Nuago Therapeutics
Ryan Humphreys
Board Member
Delphian Tx
Rafael Escandon DrPH, PhD, MPH
Former VP Clinical Ops, Labrys (acq. by TEVA)
AJOVY
Mike Rainey
Former Life Science Head
Accenture
